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Abstract
Advanced glycation endproducts (AGEs) are stable post-translational modifications of
proteins formed by the spontaneous reaction with glucose and related metabolites. Important
AGEs quantitatively are methylglyoxal (MG)-derived hydroimidazolone MG-H1, Nε-
carboxymethyl-lysine (CML) and glucosepane. They contribute to the development of
chronic kidney disease (CKD). Cellular proteolysis of AGE-modified proteins forms AGE
free adducts, glycated amino acids, which are cleared by the kidneys and excreted in urine.
Dietary AGEs mainly supplement the endogenous flux of AGE free adduct formation. AGE
free adducts accumulate markedly in plasma with decline in glomerular filtration rate. A key
precursor of AGEs is the dicarbonyl metabolite, MG, which is metabolised by glyoxalase 1
(Glo1) of the cytoplasmic glyoxalase system. Proteins susceptible to MG modification are
called collectively the “dicarbonyl proteome”. Abnormal increase of MG “dicarbonyl stress”
and is a characteristic of CKD, driven by down regulation of renal Glo1, increasing flux of
MG-H1 formation. Protein inactivation and dysfunction linked to the dicarbonyl proteome
contributes to CKD development. The receptor for AGEs, RAGE, is important in
development of CKD but its interaction with AGEs in vivo remains enigmatic; other ligands
and ternary complexation may be influential. Prevention of diabetic kidney disease (DKD) by
overexpression of Glo1 in transgenic animal models has stimulated the development of small
molecule inducers of Glo1 expression, “Glo1 inducers”, to prevent AGE formation. trans-
Resveratrol-hesperetin combination therapy is a Glo1 inducer. In clinical trial it gave a
profound improvement in insulin resistance and vascular inflammation. It may find future
therapeutic application for treatment of DKD.
Advanced glycation endproducts
Advanced glycation endproducts (AGEs) are a group of compounds formed by the
non-enzymatic reaction of reducing sugars and related metabolites with proteins and amino
acids. The process is called glycation or the Maillard reaction. Major precursors of AGEs in
vivo are the early-stage glycation adduct, Nε-fructosyl-lysine (FL), and dicarbonyl
metabolites methylglyoxal (MG), glyoxal and 3-deoxyglucosone (3-DG).1 Major AGEs
quantitatively are MG-derived hydroimidazolone MG-H1 and FL-derived Nε-carboxymethyl-
lysine (CML) and the crosslink glucosepane - Figure 1. AGEs are formed as glycated amino
acid residues of proteins which are conventionally called “AGE residues” of proteins,
although they are often called “protein-bound AGEs” in renal research. AGE-modified
proteins are degraded to related glycated amino acids, called AGE free adducts. AGEs are
also formed from glucose osmolyte, MG and other glucose degradation product dicarbonyls
absorbed from thermally processed dialysis fluids in renal replacement therapy. AGEs may
also be absorbed from glycated proteins in food, mainly as AGE free adducts. AGEs may be
quantified robustly by stable isotopic dilution analysis liquid chromatography-tandem mass
2spectrometry (LC-MS/MS).1 AGEs represent relatively long-lived and potentially damaging
post-translational modification of proteins. They are mostly damaging through modification
of functional domains of proteins, producing protein inactivation or dysfunction.
Herein we review evidence of protein-derived AGEs. There are also AGEs formed by
MG and glyoxal modification of nucleotides and basic phospholipids,
phosphatidylethanolamine and phosphatidylserine.2, 3 These have been little-studied in
chronic kidney disease (CKD)4 and so the coverage below focusses on protein-derived AGEs.
The formation of AGEs is suppressed by enzymatic metabolism of the precursor
glycating agents or glycation adduct, FL. MG and glyoxal are metabolised mainly by the
cytoplasmic glyoxalase system. The glyoxalase system consists of 2 enzymes, glyoxalase 1
(Glo1) and glyoxalase 2 and a catalytic amount of reduced glutathione (GSH). Glo1 catalyses
the GSH-dependent metabolism of MG to S-D-lactoylglutathione, and glyoxalase 2 catalyses
the hydrolysis of S-D-lactoylglutathione to D-lactate, reforming GSH consumed in the Glo1
catalysed step5 – Figure 2. 3-DG and likely also 3,4-dideoxyglucosone-3-ene (3,4-DGE)
found in thermally processed peritoneal dialysis (PD) fluids with glucose osmolyte are
metabolised by aldoketo reductases (AKRs) and aldehyde dehydrogenases. The kidney has a
very high activity of aldose reductase, ca. 2% total protein, in the inner medulla which
primarily reduces glucose to sorbitol to counter high extracellular osmotic pressure.6 Steady-
state levels of FL residues are suppressed by enzymatic metabolism by fructosamine-3-
phosphokinase, resulting in de-glycation of precursor lysine residues.1
Dicarbonyl stress
Dicarbonyl stress is the abnormal accumulation of MG and related dicarbonyl compounds,
leading to increased AGE formation and related cell and tissue dysfunction. Dicarbonyl stress
is a driver of CKD development – as evidenced by development of nephropathy in Glo1
deficient mice.7 Dicarbonyl stress may also be consequence of renal failure, as evidenced by
dicarbonyl stress with loss of clearance in bilateral nephrectomised rats.8 Dicarbonyl stress
occurs in patients with CKD,5 including accumulation of MG without increase in D-lactate in
non-diabetic subjects.9 D-Lactate is a marker of flux of formation of MG.10 This suggests the
driver of dicarbonyl stress in CKD is down regulation of Glo1 rather than increased
formation of MG in non-diabetic subjects. Decreased urinary excretion of MG is not a major
contributing factor since little MG is excreted – although this may be more important for 3-
DG.10 Down regulation of Glo1 in the kidney is a common feature of experimental diabetic
nephropathy and diabetic kidney disease (DKD). It may be driven by decreased Glo1
expression in response to hypoxia-inducible factor-1α and inflammatory signalling 
conflicting with transcription factor Nrf2, and by increased proteolysis. Overexpression of
Glo1 prevented renal senescence11 and development of diabetic nephropathy7, 12 – the latter
even when only in endothelial and tubular epithelial cells.7 This suggests reversing renal
down regulation of Glo1 may provide a new route to therapy.10
The flux of MG formation in a healthy adult human subject is ca. 3 mmol MG per 24
h and >99% is normally metabolised enzymatically. MG concentration of PD fluids, 2 – 7
µM, is therefore not a major increment to MG exposure. For 3-DG, the flux of formation is
ca. 0.13 mmol 3-DG per 24 h and ca. 90% is normally metabolised enzymatically with ca.
10% excreted. PD fluids containing 100 – 400 µM 3-DG increase exposure to 3-DG
markedly, although 3-DG has ca. 200-fold lower reactivity that MG.5, 10
Accumulation of AGEs in renal failure – the profound increase of AGE free adducts
AGE free adducts are the major form by which AGEs are eliminated from the body.
Decreased clearance in CKD markedly influences the plasma concentrations of AGE free
adducts.8, 13 The increase of AGE free adducts in clinical renal failure, studied in patients
3receiving hemodialysis (HD) and PD renal replacement therapy was 4 - 40 fold whereas the
increase in AGE residues of plasma protein was 2 – 5 fold.13 Drivers of AGE free adduct
accumulation are increased flux of formation of AGEs and decreased clearance. The flux of
formation of AGEs is indicated by the total excretion of AGE free adducts in dialysate and
urine. In PD patients, flux of AGE formation was increased markedly with respect to healthy
controls: 9-fold for MG-H1 and 2-fold for CML, pentosidine and 3-DG-derived
hydroimidazolones 3DG-H. The flux of excretion of MG-H1 free adduct in PD patients was 4
– 713 fold higher than of other AGEs, indicating MG-H1 is a dominant AGE in renal
failure.13
AGE residue contents of plasma protein have been studied as biomarkers of mortality
risk in renal failure with contrary outcomes or low marginal increased relative risk.14, 15
Plasma protein AGEs, such as MG-H1 and 3DG-H, may be increased by dicarbonyl stress;13
CML and glucosepane may be increased by elevated FL residue precursor and/or decreased
FL metabolism;16-18 and pentosidine residue content may be increased by elevated
pentosephosphate pathway activity providing increased level of the pentose precursor.19 AGE
residue content of plasma protein is also influenced by decreased residence time of albumin
in the vascular compartment by albuminuria,20 increased transcapillary escape rate –
influenced by hypertension and atherosclerosis;21 and also by decreased albumin synthesis
and catabolism.22 These confounders suggest AGE residue content of plasma protein has a
complex relationship with clinical outcomes in CKD.
An indication of increased AGE formation in the kidney may be gained by measuring
total body flux of formation of AGEs, or surrogate measures thereof: such as urinary or
dialysate flux of AGE free adducts, plasma AGE free adduct concentration corrected for
decline in glomerular filtration rate (GFR) in CKD stages G1 – G4, and plasma AGE free
adduct concentration immediately prior to a dialysis session in HD patients or dialysis fluid
exchange in PD patients. Correction may be made for contributions from food AGEs – see
below.
Measurement of AGEs for assessment of risk of development and progression of CKD
In a large cross-sectional study, increased serum CML measured by a competitive
immunoassay was associated with CKD and negatively associated with GFR.23 The
immunoassay used measured both serum protein CML residues and CML free adduct
concurrently.24 CML free adduct is most sensitive to loss of renal clearance8 and so such
immunoassay formats may be reflecting accumulation of CML free adduct. Total plasma
AGEs, the sum protein residues and free adducts, the sum of AGE residues of protein and
AGE free adduct, of selected types are determined by analysis of acid hydrolysates of plasma.
Total plasma CML and CEL were increased in patients with type 1 diabetes and decreased
GFR, compared to those with normal GFR, and were linked to markers of endothelial cell
dysfunction - von Willebrand factor, soluble vascular cellular adhesion molecule-1
(sVCAM1), and soluble thrombomodulin – independent of GFR.25 Total plasma pentosidine
was a risk predictor of mortality in CKD after adjusting for all confounders.26 In recent
studies of AGEs and related analysis of skin collagen in patients with type 1 diabetes, an
analyte panel of glucosepane, MG-H1, CML, Nε(1-carboxyethyl)lysine (CEL), glyoxal-
derived hydroimidazolone (G-H1), pentosidine, furosine, collagen ﬂuorescence, skin collagen 
acid solubility and pepsin digestibility were linked to risk of progression of diabetic
nephropathy; with the FL-linked analyte furosine being the strongest predictor.27 In contrast,
CML residue content of plasma protein was not linked to the risk of developing diabetic
nephropathy.28 Plasma MG-H1 free adduct concentration was an independent risk predictor
for progression of DKD.29 Low molecular weight AGE fluorophore measurement was a
mortality predictor in HD patients.30
4Skin autofluorescence (SAF) has been proposed as an non-invasive measure linked to
the dermal content of AGEs.31 Spectrofluorometric analysis and scanning confocal
microscopy and multi-photon excitation microscopy found that major contributions to SAF
are from NAD(P)H, flavin adenine dinucleotide and porphyrins.32, 33 There are also
contributions from the oxidative fluorophore, N-formylkynurenine, and trace fluorescent
AGEs such as pentosidine and others.31 Weaknesses of this approach are that SAF has
important non-AGE contributions and the major quantitative AGEs in CKD, MG-H1 and
CML, are not fluorescent. Change in SAF is likely reflecting a combination of metabolic
dysfunction and protein-derived fluorophores in CKD. In assessment of risk of progression of
CKD, an optimum cut-off level of SAF gave sensitivity 0.74 and specificity of 0.73 for CKD
progression34 and SAF was also linked to mortality risk in renal failure.35
Revisited and new and concepts in AGE-related pathogenesis
The AGE receptor hypothesis revisited
It was proposed that AGE-modified proteins bind specifically to cell surface receptors to
activate cell dysfunction. This was questioned and considered limited to proteins structurally-
damaged and/or glycated to high, supraphysiological extents prepared in vitro.36, 37 An AGE
receptor found influential on the development of experimental diabetic nephropathy and
DKD is the receptor for advanced glycation endproducts, RAGE. Transgenic mice
overexpressing RAGE showed glomerular hypertrophy, increased albuminuria, mesangial
expansion, advanced glomerulosclerosis, and increased serum creatinine compared to non-
transgenic diabetic littermates.38 RAGE-deficient mice show decreased albuminuria,
hyperfiltration and glomerulosclerosis compared with diabetic wild-type controls.39 RAGE
expression is increased in peripheral blood monocytes in clinical CKD.40
The use of albumin highly glycated by AGEs, dissimilar from albumin which is
minimally modified by AGEs in vivo, has made studies of the metabolism and functional
responses induced by AGE-modified proteins by RAGE and other putative AGE receptors
difficult to understand and interpret. Typical glucose-derived AGE-modified albumin
prepared in vitro had ca. 7,000 Da mass increment of glycation adducts, ca. 40 – 50 molar
equivalents of modification, markedly increase negative charge, bound to RAGE and had
rapid clearance by scavenger receptor-mediated removal from circulation in the liver.41-43 In
contrast, albumin in vivo typically has <1% modification by one AGE residue, a mass
increment of <200 Da (mostly due to early glycation adduct FL), little change in charge, may
not always bind RAGE and shows little extraction from circulation in the liver.13, 22, 41, 44-46
Mathematical modelling of glycation kinetics and protein turnover supports experimental
findings of low extents of protein glycation in vivo.22, 47 Protein glycation may reach it
highest extent of modification for long-lived basement membrane proteins of the peritoneal
cavity basement membrane for renal failure patients receiving long term treatment with PD
fluids containing high concentrations of glucose osmolyte. Since RAGE activation is not
limited to these conditions, it is likely that ligands other than highly glycated proteins are
important agonists for the RAGE receptor physiologically.
Ligand binding studies of RAGE have often been performed with albumin highly
modified with AGEs where competitive binding and deductions from crystallographic data of
RAGE suggest interaction is driven by the high negative charge of this ligand48, 49. There are
doubts, therefore, if such interaction is found in vivo. Further studies characterised the
binding affinities of major AGE residues and AGE free adducts to RAGE by measuring
changes of intrinsic tryptophan fluorescence and high resolution nuclear magnetic resonance
(NMR) chemical shifts of peptide backbone of the extracellular domain of RAGE.50, 51 Herein
binding affinities were used to deduce percent RAGE occupancy by AGEs in vivo. CML and
CEL free adducts did not bind to RAGE; and CML and CEL residues had very low affinities
5for RAGE such that predicted receptor occupancies in healthy controls and HD patients in
vivo are very low; only 3 – 8%. This is contrary to initial findings which involved use of
CML-modified albumin prepared by chemical reductive alkylation of albumin.52 Chemically
generated CML-modified albumin may have damaged albumin structurally, producing
anomalous aggregates which bound to RAGE. In contrast, MG-H1 and related structural
isomers, residues and free adducts, have ca. 2000-fold higher affinity for RAGE, suggesting
MG-derived hydroimidazolone is recognised specifically50 – Table 1. Albumin modified
minimally by MG containing mainly MG-H1 residues was found previously to bind RAGE.46
The unexpected finding, however, is that RAGE is always saturated with MG-H1 modified
protein in healthy subjects and CKD patients, suggesting that this binding may is non-
productive for activation of signal transduction. RAGE was recently found to have a high
affinity homophilic binding with KD of 470 nM mediating cell-cell interaction. Hence,
normally much of the cellular RAGE protein pool may not be available for AGE-modified
protein binding and competent to activate related signal transduction.53
Heparan sulfate-RAGE complexes were found to be essential for signal transduction
of RAGE activated by AGE-modified albumin, high mobility group protein 1 (HMGB1) and
S100 proteins.54 Signalling downstream from RAGE-heparan sulfate-activating ligand
ternary complex studied to date involved extracellular regulated kinase-1 and -2 and p38
MAP kinase phosphorylations. Erk activation mediates pro-fibrotic responses and
extracellular matrix expansion.55 p38 MAP kinase activation is linked to endothelial
permeability, inflammation and renal fibrosis.56-58 Interplay of heparan sulfate and heparanase
in CKD may influence the signalling competence of MG-H1 with RAGE.59 Down regulation
of RAGE expression may have beneficial responses, independent of the activating ligand, by
countering the increased expression of CKD.60 Decreased activity of RAGE is associated
with decreased podocyte production of monocyte chemoattractant protein-1 (MCP-1),61
decreased monocyte recruitment, glomerulosclerosis, extracellular matrix accumulation,
albuminuria and decline in renal function.62-64
Dicarbonyl proteome
Protein dysfunction and inactivation is produced directly by formation of MG-H1 and similar
hydroimidazolone AGEs on functional arginine residues of proteins. This likely makes a
major contribute to AGE pathogenesis in CKD because: (i) MG-H1 is the AGE of highest
flux of formation in CKD; (ii) MG-H1 formation produces loss of charge and all electrostatic
interactions of arginine residue modification, eliminating functional interactions and
activities; (iii) arginine residues have a high probability of location in functional domains of
proteins (20%); and (iv) MG modification tends to occur on functionally-important arginine
residues. Proteins modified by MG and related dicarbonyl metabolites are called collectively
the “dicarbonyl proteome”. Examples of protein targets of MG glycation are: collagen-4 –
preferentially modified by MG at integrin binding sites driving endothelial cell detachment,
increased circulating endothelial cells and vascular damage;65 mitochondrial proteins –
leading to increased formation of reactive oxygen species;66 LDL - inducing pro-atherogenic
transformation to small dense LDL driving dyslipidemia;67 p65 of the NF-kB system -
leading to increased expression of RAGE and S100A8, S100A12, and HMGB1 and enhanced
and persistent vascular inflammation;68 and apolipoprotein-A1 - inducing de-stabilisation of
HDL, contributing to dyslipidemia.69 Effects of the dicarbonyl proteomes may be modelled in
vitro by silencing of Glo1. In endothelial cells this triggered increased expression of
collagens-1 and -5, endothelin-1, ICAM-1, VCAM-1 and of MCP-1;70 and in L6 myoblasts
increased collagen-1 and -4.71 This suggests that dicarbonyl stress is a driver of vascular renal
inflammation and renal and muscle fibrosis – considered critical to CKD progression and co-
morbidities - cardiovascular disease and muscle wasting.72, 73 The dicarbonyl proteome may
6be characterised by high resolution mass spectrometry of tryptic digests of cell protein
extracts.74 This remains to be applied to renal cells and tissue extracts.
Contribution of food AGEs to clinical AGE exposure and health impairment
There is a high content of AGEs in sugar-rich, thermally processed foods. The clinical impact
of dietary-derived AGEs remains uncertain. It may be particularly important in CKD where
clearance and excretion of AGEs is impaired. Advance on this has been stymied by lack of
experimental evidence on the amount of AGEs absorbed from food. Dietary AGEs have low
bioavailability. An approach to resolve these is to exploit the measurement of pyrraline – an
AGE found exclusively in food75, 76 – Figure 3. Urinary excretion of AGE free adducts
provides an estimate of total body AGE exposure and urinary exertion of pyrraline reflects
absorption of AGEs from food. Correlation of urinary excretion of a particular AGE with
urinary exertion of pyrraline reflects a significant contribution of the AGE from food. Linear
regression of urinary AGE excretion on urinary exertion of pyrraline and extrapolation to
zero pyrraline excretion gives an estimate of the flux of AGE formed endogenously in the
body. AGE absorbed from food then equals the total urinary AGE flux minus this deduced
endogenous AGE flux.77 This analysis was performed recently for MG-H1. In healthy
overweight and obese subjects, the flux of endogenous formation of MG-H1 at baseline was
ca. 13 nmol/mg creatinine, representing 68% of total MG-H1 exposure; the mean
contribution to total MG-H1 exposure from the diet was 32% but highly variable.77 Similar
studies are now required in CKD patients. The diet is likely often a minor source of MG-H1
exposure.
Several clinical studies with interventions to decrease exposure to dietary AGEs in
CKD for improved vascular health have been performed, with often assessment of markers of
vascular inflammation.78, 79 These and other studies were evaluated by meta-analysis for
overall assessment of evidence of health benefits.80 There are difficulties of interpretation as
unblinded study designs were used. It was concluded that there is insufﬁcient evidence, at 
present, of health benefit to recommend dietary AGE restriction in patients with CKD.80 An
advance that was thought would improve studies of this type was direct determination of the
proportions of AGEs exposure originating from the diet endogenous origin. This has recently
been provided77 – see above. There is a need for long-term, high-quality randomised
controlled trials with large sample size and masking of the AGE intervention to provide more
robust evidence on the health impact of dietary AGEs in CKD – also taking advantage of
recent advances in improved quantitation of AGEs in food.81 In preclinical studies, it was
found that diabetic mice on a low AGE diet still developed diabetic nephropathy.82 A recent
open label, pilot study found effects of a high AGE diet on intestinal microbiota in renal
failure patients receiving PD therapy.83
AGEs formed endogenously in proteins are likely the most damaging to physiological
function. Dietary AGEs are absorbed as free adducts after digestion or as peptides which are
hydrolysed by peptidases to AGE free adducts after absorption.22 To date, there is no
evidence that AGE free adducts from food may be incorporated into endogenous proteins but
they may equilibrate with pools of AGE free adducts in plasma and tissues. Endogenous flux
of formation of MG-H1 and other AGEs may be improved AGE-related clinical biomarkers
to assess association with progression of CKD and risk of associated co-morbidities.
AGE-related therapeutics - Glyoxalase 1 inducers
Glycation by dicarbonyls is non-oxidative and so it is insensitive to antioxidants. It requires a
new type of pharmacological agent for therapy. Experimental agents have been developed to
scavenge reactive dicarbonyls and an existing therapeutic agent for patients with type 2
diabetes (T2DM), metformin, also reacts with MG. These provide ineffective removal of MG
7compared to in situ activity of Glo1 – Table 2. Decrease of MG levels in patients with T2DM
treated with metformin84 is likely mainly achieved through increase in glycaemic control.85
Therapeutic agents that induce Glo1 expression may be better because: (i) Glo1 metabolises
>97% of MG formed in human metabolism;10 (ii) they correct decreased renal Glo1 activity
which is a common characteristic of animal models of DKD;86-88 and (iii) pre-clinical studies
showing decreased Glo1 expression potentiates and overexpression of Glo1 prevents the
development of diabetic nephropathy.7, 12, 89
Small molecule inducers of Glo1 expression or “Glo1 inducers” may be developed as
activators of Nrf2, exploiting a regulatory antioxidant response element (ARE) in the GLO1
gene. Glo1 inducers decreased cellular and extracellular concentrations of MG, MG-derived
AGE formation and related functional impairment - such as endothelial attachment to
collagen-4.90 We screened Glo1 inducers with a functional assay based on GLO1-ARE linked
expression.90 The best Glo1 inducer was a combination of trans-resveratrol (tRES) and
hesperetin (HESP), tRES-HESP.77
tRES-HESP combination was evaluated in Phase 1 clinical trial in overweight and
obese subjects to establish safety and target pharmacology. Functional assessments of
metabolic health were also included - Phase 2A trial for metabolic health benefit in obesity.
The study was a randomized, double blind, placebo-controlled crossover study in 29 subjects.
Dosing was by oral capsule, once daily, containing tRES-HESP or placebo. Dosing periods
were 8 weeks with 6 weeks washout between in the crossover period. Urinary excretion of
tRES and HESP metabolites was increased >2000-fold and >100 fold, respectively, compared to
placebo. Clinical safety indicators were normal at study entry and remained unchanged
throughout the placebo and tRES-HESP treatment periods. tRES-HESP treatment produced a
22% increase in Glo1 activity of peripheral blood mononuclear cells (PBMCs) of all subjects,
compared to placebo. The increase was 30% in the obese sub-group (subjects with BMI ≥ 30 
kg/m2). Concomitant with increased Glo1 activity, there was a 37% decrease in plasma MG
post-supplementation with tRES-HESP but not with placebo. The flux of endogenously-
generated MG-H1 adducts was ca. 13 nmol/mg creatinine at baseline and decreased by 14%
with tRES-HESP treatment but not with placebo.77
tRES-HESP treatment produced a profound effect on glucose metabolism. Insulin
resistance was corrected to levels typical of lean subjects with normal insulin sensitivity;
dysglycaemia was improved - fasting plasma glucose decreased 5% and 2-h area-under-the-
curve plasma glucose in an oral glucose tolerance test decreased 8%. This suggests tRES-
HESP may be highly beneficial for treatment of insulin resistance in CKD. Other changes were:
3% increase in eGFR and 9% decrease in plasma urea with tRES-HESP. The study
participants had stages G1 and G2 CKD with renal function assessments were made at only
once at study visits and so these responses require validation in further studies and advanced
stages of CKD.
There was also a profound effect of tRES-HESP on inflammatory gene expression,
assessed in PBMCs. In all subjects there was a 30% decrease of prostaglandin-endoperoxide
synthase 2 (PTGS2 or COX2) and 39% decrease of interleukin-8 (IL-8). In the highly-
overweight subgroup there was also marked decreases of RAGE (37%) and MCP-1 (49%).
Treatment with placebo produced no change. Inhibition of RAGE and MCP-1 signalling are
targets for drug development in CKD.
The health beneficial effects of tRES-HESP have not been achieved by these compounds
individually, even at markedly higher doses.91, 92 The likely explanation for this is synergistic
pharmacological effects in activation of Nrf277 and improved bioavailability of tRES through
inhibition of intestinal glucuronosyltransferases by HESP.93 If confirmed, this circumvention
of bioavailability problems of tRES may be a major advance to translating promise of health
benefits of tRES for clinical applications – Figure 5. In experimental models of DKD, tRES
8and hesperidin – a glycoside derivative of HESP, decreased albuminuria, glomerular matrix
expansion, inflammation and renal function decline, albeit at doses that are not translatable
clinically.94, 95
The Glo1 inducer appears to be particularly appropriate and timely for treatment of
CKD, addressing multiple targets of cell and tissue dysfunction. It may correct renal
extracellular matrix disposition and dysfunction, fibrosis and inflammation – allowing for re-
engagement of podocyte food processes and re-establishment of normal glomerular
endothelial cell, mesangial cell and fibular cell function to re-instate the glomerular filtration
barrier and improve GFR – Figure 4. Some of the benefits of tRES-HESP may be due to
concurrent induction of increased expression of other protective ARE-linked genes -
including protection against other dicarbonyls since expression of AKRs was also induced.77
Concluding remarks
It is likely that dicarbonyl stress and increased formation of MG-H1 is a key contributory
factor in the development of CKD for which down regulation of renal Glo1 appears to be a
key driver. Correction of this by Glo1 inducers offers a new strategy for treatment and
measurement of flux of MG-H1 new companion diagnostics to guide their use in precision
medicine. New features of AGE research in CKD are summarised in Table 3.
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Table 1 │Binding affinities and predicted in vivo occupancy of RAGE with AGE residues and AGE free adducts.
Ligand KD (μM) [AGE], healthy control





CML residue 87 2.3 and 8.0 2.6 8.4
CEL residue 93 1.1 and 2.6 1.2 2.7
MG-H1 residue 0.040 12.8 and 22.0 99.7 99.8
MG-H1 free adduct 0.040 0.12 and 4.8 54.9 99.0
G-H1 free adduct 0.043 0.04 and 0.26 21.6 32.7
RAGE 0.47 0.13 and 0.73 18.4 45.7
Assumptions: RAGE protein copy number in human monocytes in vivo was 37,000 and 208,000 per cell in healthy subjects and HD patients,
respectively,40 equivalent to a concentration of ca. 130 and 730 nM. KD and AGE concentration values as given.13, 50, 51 Receptor occupancy was
determined by deducing the equilibrium position of the binding equation AGE + RAGE = AGE-RAGE.
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Table 2 │ Experimental therapeutic agents to counter dicarbonyl stress.
Agents Mechanism of action Advantages/advantages
Glo1 inducer Increased expression of
Glo1 (high efficiency
catalytic removal of MG
and glyoxal)
Corrects deficiency of Glo1 in the kidney and elsewhere driving dicarbonyl stress-
induced mechanisms of CKD.88 Limited to effects on Glo1 substrates. Induction occurs
rapidly within a few hours and is relatively long lasting; Glo1 half-life is 2 – 3 days.77, 90
Metformin Dicarbonyl scavenger
(stoichiometric removal)
Known pharmacological and safety profile. Reacts with MG to form mainly
hydroimidazolone-like and also triazepinone adducts but they are quantitatively minor





Aminoguanidine reacts with MG and other dicarbonyls to form 3-amino-1,2,4-triazine
derivatives.98, 99 At peak concentration, aminoguanidine is an effective MG scavenger in
plasma but not inside cells where it is expected to compete ineffectively with Glo1 but
this is short-lived; plasma half-life is ca. 1.4 h. 100 In clinical trial adverse effects were
gastrointestinal disturbance, abnormal liver function tests, ﬂu-like symptoms and a rare 
vasculitis.101 Clinical therapeutic development was questioned further when kidney







PTB is an efficient scavenger of MG; ca. 6-fold more effective than aminoguanidine under
physiological conditions.98, 103 Unstable under physiological conditions, degrading by
hydrolysis with a half-life of 44 min.104 An effective MG scavenger in plasma for a short
period but not inside cells where it is expected to compete ineffectively with Glo1.
Alagebrium shows similar properties.105 It improved albuminuria in experimental diabetic
nephropathy.106 A Phase 2 clinical trial in patients with type 1 diabetes and




Well tolerated. Relatively low reactivity with dicarbonyls.107 May function through other,
non-AGE mechanisms (supplementation of vitamin B6 metabolism).108 Judged to have
failed in phase 2 clinical trial for treatment of diabetic nephropathy.109
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Table 2 │ Experimental therapeutic agents to counter dicarbonyl stress (cont’d).






Well tolerated but poor scavenger activity: median effective concentration of arginine in
an ex vivo model of plasma protein glycation was 23 mM.110 These agents are competing
with high endogenous cellular and extracellular arginine residue concentrations; ca. 20 mM
and 80 mM, respectively. Improved MG scavenging was found with arg-arg and arg-lys
residue containing peptides.86, 111
TTP488 (PF-
04494700)
RAGE inhibitor May block RAGE signalling.112 It was evaluated in Phase 2 clinical trial for DKD (6 month
treatment, 110 patients). It failed to show effect on urinary albumin-creatinine ratio, eGFR
or potential markers of RAGE inhibition.113
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Table 3 │ New features of AGEs in CKD.
Feature Description Key evidence Reference
Dicarbonyl stress Dicarbonyl stress is a driver of CKD
development which is exacerbated as CKD
progresses.
Glo1 silencing in mice imposes a nephropathy
phenotype. Experimental and clinical advanced
CKD exhibit dicarbonyl stress.
5, 7, 8
MG accumulation is of
endogenous origin
MG accumulation is driven by down regulation
of Glo1 in CKD. Endogenous flux of MG
formation far exceeds MG of exogenous origin
Expression and activity of Glo1 is down
regulated in experimental CKD. D-Lactate
concentration is not increased in CKD.
9, 10
MG-H1 is a major
challenge to proteostasis
in CKD
MG-H1 formation impairs protein function and
increased in CKD
Dicarbonyl proteome and flux of MG-H1
increased 9-fold in CKD; 4 – 713 fold higher
flux that other AGEs.
13, 67
AGE/RAGE interaction Functional activity of AGEs with RAGE is
uncertain
CML and CEL residues have too low affinities
to bind RAGE in vivo; MG-H1 binds RAGE
but binding is always saturated
13, 50, 51
Dietary AGEs The amount of AGEs absorbed from the diet
may be deduced from urinary AGE and
pyrraline fluxes.
Regression of urinary MG-H1 excretion on
urinary pyrraline excretion.
77
Glo1 inducer therapeutics Small molecule inducers of Glo1 expression to
counter down regulation of renal Glo1 in CKD.
tRES-HESP combination evaluated in Phase




Figure 1 | Major AGEs in chronic kidney disease.
Figure 2 | The glyoxalase system. Schematic of the glyoxalase metabolic pathway.10
Figure 3 | Pyrraline – an AGE exclusively of dietary origin.
Figure 4 | Expected mechanism of action of glyoxalase 1 inducers in chronic kidney
disease. Evidence form studies of Glo1 functional genomics and Glo1 overexpression, Glo1
inhibitor and MG treatment of renal cells in vitro. Abbreviations: SELE, E-selectin; VCAM-
1, vascular cell adhesion molecule-1; Tie2, tyrosine-protein kinase cell-surface receptor for
angiopoietin-1, angiopoietin-2 and angiopoietin-4; VEGF, vascular endothelial growth factor;
TGFbeta, transforming growth factor-beta.
Figure 5 | Circumventing the problem of low bioavailability of trans-resveratrol
Impairment of glucuronidation of trans-resveratrol and hesperetin in the small intestine
by co-administration at pharmaceutical doses. Comparison of the demands on
glucuronidation in the intestinal epithelium when tRES alone or in combination with HESP
are administered. Abbreviations: HESP-3’-O-G, hesperetin-3’-O-glucuronide; HESP-7-O-G,
hesperetin-7-O-glucuronide; tRES-3-O-G, trans-resveratrol-3-O-glucuronide; tRES-4’-O-G,
trans-resveratrol-4’-O-glucuronide.
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